01—Abstract
Summary
Summary of the 10-K filed June 23, 2015. Cited figures are marked; the original filing is the authoritative source.
Medtronic plc's 10-K filing for the fiscal year ended April 23, 2015, highlights a transformative year dominated by the significant acquisition of Covidien plc for approximately $50 billiona.
This strategic move dramatically expanded Medtronic's global footprint, product portfolio, and market reach, integrating Covidien's minimally invasive therapies, surgical solutions, and patient monitoring products into Medtronic's existing offerings across its Cardiac and Vascular, Restorative Therapies, and Diabetes segments. The company demonstrated resilience with a reported 19% increase in net sales to $20.261 billionb, driven by organic growth in its established segments and the inclusion of Covidien's results for one quarter. Despite increased acquisition-related expenses and a slight dip in net income and diluted EPS compared to the prior year, the company's operational strategies, including therapy innovation and globalization, were amplified by the Covidien integration.
Investors should note the substantial goodwill and intangible assets added to the balance sheet as a result of the acquisition, which will significantly influence future financial reporting and amortization expenses. Medtronic's commitment to research and development remains strong, with $1.640 billionc invested in fiscal year 2015, although this represented a slightly lower percentage of net sales.
The company's financial position remains robust, supported by strong cash flow from operations and a well-managed debt structure despite the increased leverage from the Covidien transaction. The report indicates a focus on further integrating operations and realizing synergies from the acquisition, setting the stage for future growth and market leadership.
02—Key points
Key Highlights
- Completed the $50 billion acquisition of Covidien plc on January 26, 2015, significantly expanding Medtronic's global scale and product offerings.
- Reported a 19% increase in net sales to $20.261 billion for fiscal year 2015, driven by organic growth and the inclusion of Covidien's results.
- Invested $1.640 billion (8.1% of net sales) in research and development, underscoring a commitment to innovation.
- Organized into four new operating segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes.
- The Cardiac and Vascular Group reported $9.361 billion in net sales, showing a 6% increase.
- The Restorative Therapies Group reported $6.751 billion in net sales, a 4% increase.
- The Diabetes Group reported $1.762 billion in net sales, a 6% increase.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2015, Medtronic plc kept $0.13.
- Revenue$20.26B100.0%
- Cost of revenue−$6.31B31.1%
- Gross profit$13.95B68.9%
- Operating costs−$10.19B50.3%
- Operating income$3.77B18.6%
- Interest, other & tax−$1.09B5.4%
- Net income$2.67B13.2%
Where FY2015 revenue went
$20.26B- SG&A: $6.90B, 34% of revenue
- Cost of revenue: $6.31B, 31% of revenue
- Other operating costs: $3.28B, 16% of revenue
- Net income: $2.67B, 13% of revenue
- Interest, other & tax: $1.09B, 5.4% of revenue
Kept 13% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2015filed June 23, 2015Financial Statements
FY2015 against FY2014
| Line item | FY2015FY2014 | Change |
|---|---|---|
| Revenue | $20.26B$17.00B | +19.1% |
| Cost of Revenue | $6.31B$4.33B | +45.6% |
| Gross Profit | $13.95B$12.67B | +10.1% |
| SG&A Expenses | $6.90B$5.85B | +18.1% |
| Operating Income | $3.77B$3.81B | −1.2% |
| Interest Expense | $666.00M$379.00M | +75.7% |
| Net Income | $2.67B$3.06B | −12.7% |
| EPS (Basic) | $2.44$3.06 | −20.3% |
| EPS (Diluted) | $2.41$3.02 | −20.2% |
| Shares Outstanding (Basic) | 1.10B1.00B | +9.3% |
| Shares Outstanding (Diluted) | 1.11B1.01B | +9.4% |
05—Questions
Frequently Asked Questions
What was the primary driver of Medtronic's financial performance in fiscal year 2015?
The primary driver of Medtronic's financial performance in fiscal year 2015 was the monumental acquisition of Covidien plc, completed on January 26, 2015, for approximately $50 billion. This acquisition significantly impacted net sales and operational structure, though Covidien's results were only fully reflected for the last quarter of the fiscal year.
How did the Covidien acquisition affect Medtronic's reported sales and profitability?
The acquisition of Covidien led to a 19% increase in net sales to $20.261 billion for fiscal year 2015. However, net income decreased by 13% to $2.675 billion, and diluted earnings per share fell by 20% to $2.41, largely due to acquisition-related expenses and the inclusion of only one quarter of Covidien's results, impacting comparability with the prior year.
What are Medtronic's key growth strategies as outlined in the filing?
Medtronic's primary strategies are Therapy Innovation, Globalization (with a focus on emerging markets), and Economic Value (achieved by offering new services and solutions to improve outcomes and efficiencies, reduce costs, enhance remote clinical management, and increase patient engagement).
How is Medtronic's business structured following the Covidien acquisition?
Following the Covidien acquisition, Medtronic reorganized into four operating segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.
What is the outlook for Medtronic's R&D spending?
Medtronic invested $1.640 billion (8.1% of net sales) in R&D in fiscal year 2015. The company expects R&D spending as a percentage of net sales to range between 7% and 8% in fiscal year 2016, partly due to the scale of the Covidien acquisition.
06—Continue